Informa Markets says its ninth edition of PharmaLytica, a premier pharmaceutical exhibition, was a big success in HITEX, Hyderabad, 1-3 June.
The three-day event hosted over 150 exhibitors and served as a testament to India’s vision of becoming the pharmacy of the world.
The future of pharma leveraging robotics and digitalisation was discussed and automated systems displayed.
Key stakeholders from the Pharmaceutical Industry were present in Hyderabad, including chief guest Shri Jayesh Ranjan, IAS, principal secretary, Industries & Commerce Dept, Government of Telangana; R.K. Agrawal, national president, Bulk Drug Manufacturers Association of India (BDMAI) and Harish Jain, president, Karnataka Drugs & Pharmaceutical Manufactures (KDPMA), as well as Yogesh Mudras, MD, Informa Markets in India, and Rahul Deshpande, senior group director, Informa Markets in India.
Shri Jayesh Ranjan said: “The pharmaceutical, biotechnology, and medical devices industry in Telangana has experienced remarkable growth, surpassing initial expectations. Initially projected to reach $100bn in 10 years, the industry already reached a substantial size of $80bn, prompting a revision of the 10-year target to $250bn. This buoyancy reflects the industry’s potential and highlights the need for the sector to showcase advanced and sophisticated technologies, moving beyond bulk manufacturing.”
R.K. Agrawal added that the pharmaceutical industry had moved towards transparency and visibility, where maintaining comprehensive and digitised records is an imperative to showcase processes, testing, and manufacturing to regulatory authorities during audits. Automation and technological advancements were, he said, increasing efficiency and reducing reliance on manual labour. He added that the Indian government’s supportive policies such as streamlining regulatory processes, promoting research and development, and encouraging investments had created a conducive environment for industry growth.
The sector grew at a rate of 5% during the pandemic and was now expected to grow at a rate of over 8%. Bulk Drugs made up 25% ($15bn) of the Indian pharma industry and once the new Pharma City comes up in Telangana state is likely to further attract more FDI.
Harish Jain said India’s aspirations in the pharmaceutical industry go beyond its current ranking of 14th in value. The aim is to break into the top five “Events like PharmaLytica served to enhance awareness about the latest advancements in equipment, testing methods, and machinery, enabling us to stay informed about emerging technologies,” Jain added.
Hyderabad is known as the Pharma hub of India and there are 214 US FDA-approved facilities in Hyderabad.
Shankar Gupta, chief sales officer, ACG, said: “Events like the one organised by Informa Markets are instrumental in promoting the Indian pharmaceutical industry on an international scale. We were determined to seize this opportunity and propel ourselves to greater heights.”
PharmaLytica’s exhibitors included Advanced Expertise Technology, Allyone Environmental Technologies, Burkert India, IFB Industries, Indu IonPure, Integrated Cleanroom Technology, Labtop Instruments, Lennox Clean Air Technologies, Nicomac Taikisha Clean Rooms, NKP Pharma, Peppermint Robots, Petals Engineers, Scientific Research Instruments Company, Standard Group of Companies, TESTO India, Watermass Systems, and more.